Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Autors principals: Qiao Liu (Autor), Zhen Zhou (Autor), Xia Luo (Autor), Lidan Yi (Autor), Liubao Peng (Autor), Xiaomin Wan (Autor), Chongqing Tan (Autor), Xiaohui Zeng (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...